On February 27, 2020 RareCyte reported a liquid biopsy blood test for programmed death-ligand 1 (PD-L1), enabling customers to evaluate PD-L1 expression on circulating tumor cells (CTCs) with industry leading sensitivity. PD-L1 is a biomarker that directs checkpoint inhibitor immunotherapy treatment and liquid biopsy offers a noninvasive method to evaluate biomarker expression for treatment selection and patient monitoring in clinical research (Press release, RareCyte, FEB 27, 2020, View Source [SID1234554946]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
With the RareCyte PD-L1 assay and the AccuCyte-CyteFinder system, blood from a single tube is processed to cells for CTC enumeration and PD-L1 biomarker expression analysis, and to plasma for optional cfDNA analysis. Single CTCs can also be retrieved using the CytePicker Module for sequencing analysis. As a result, the RareCyte assay provides the first comprehensive liquid biopsy solution for PD-L1 analysis.
The PD-L1 Panel Kit was validated based on rigorous requirements set to clinical standards. Tad George, PhD, SVP of Biology R&D at RareCyte noted, "Our approach to assay development and validation is centered on creating globally deployable products that combine the sensitivity, specificity, and precision required for multi-center clinical trials for CTC enumeration and phenotyping. In addition, the RareCyte platform enables cell-free DNA analysis on the same sample, providing a comprehensive assessment of patient status."
Joe Victor, CEO of RareCyte, said "We released this new assay as a response to customer feedback from an earlier generation assay still in use today and we anticipate that this PD-L1 Panel Kit will be utilized in a variety of exploratory clinical research this year." The PD-L1 Panel Kit is now available for purchase. More information on the PD-L1 Panel Kit and the RareCyte platform is available at View Source
RareCyte products are for research use only. Not for use in diagnostic procedures.